Secondary hormonal therapy for advanced prostate cancer.
about
Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosisTherapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerFlap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason scoreTRPV6 determines the effect of vitamin D3 on prostate cancer cell growthDoes Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis?Abiraterone and increased survival in metastatic prostate cancerAge disrupts androgen receptor-modulated negative feedback in the gonadal axis in healthy men.HE3235 inhibits growth of castration-resistant prostate cancer.Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world dataPhase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapySafety of antiandrogen therapy for treating prostate cancer.Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).Comparison of ketoconazole and estramustine for treating patients with castration-resistant prostate cancerThe curcumin analog ca27 down-regulates androgen receptor through an oxidative stress mediated mechanism in human prostate cancer cells.Clinical significance of free-to-total prostate-specific antigen (PSA) ratio in advanced prostate cancer patients with PSA less than 0.1 ng/ml after hormone treatmentksRepo: a generalized platform for computational drug repositioningOral low-dose dexamethasone for androgen-independent prostate cancer patients.Does failure of single hormone therapy delineate hormone refractoriness for prostate cancer?Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer.Current treatment strategies for castration-resistant prostate cancerNuclear receptors and endobiotics glucuronidation: the good, the bad, and the UGT.Subcapsular orchiectomy in the primary therapy of patients with bone metastasis in advanced prostate cancer: an anachronistic intervention?Drug discovery in advanced prostate cancer: translating biology into therapy.Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review.Androprostamines A and B, the new anti-prostate cancer agents produced by Streptomyces sp. MK932-CF8.Cardiovascular toxicities of systemic treatments of prostate cancer.Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity.Anti-cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF-κB.A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer.Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 StudiesSIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomasProstate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients.Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade.Docetaxel as a vital option for corticosteroid-refractory prostate cancer.Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model.Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer.Efficacy and safety of different interventions in castration resistant prostate cancer progressing after docetaxel-based chemotherapy: Bayesian network analysis of randomized controlled trials.Efficacy of treatment with a GnRH antagonist in prostate cancer patients previously treated with a GnRH agonist.PSA response following the 'steroid switch' in patients with castration-resistant prostate cancer treated with abiraterone: A case report
P2860
Q24680255-D3026261-03D2-4F76-A4DB-DF04BDD72F18Q26750620-F4E073B7-7DA1-4686-808A-FAE1C77AA122Q28255097-D1DB2657-5BBE-4B7D-972E-F8F1C956AB9FQ28477138-844CCEA6-748D-445D-A494-108E9F12B96EQ28552864-CB8B9E53-E696-4215-B355-317DF71A02FFQ29617512-A9F16874-DA98-4B7C-BAAF-D1E65FFDAD70Q30430407-B36A8C9B-1858-431A-A1BE-8B6DD0C27E25Q30491204-F61CE4E6-FE14-417D-9113-3FDF090A95ECQ31034242-19F13D5D-9BC5-4D6C-80AA-600BD5A94D3FQ33775549-061149AD-0C45-41C4-817A-44FC49FB7732Q34441134-CAC36372-4233-4ABF-84A2-C3C67AF8D250Q34900827-723A0ED8-6EA6-4CD7-B4FF-2F6DE033D083Q35624514-166743BD-BA75-4C94-8E8D-710F15E2A283Q35843081-E73534AE-31F6-402D-9E86-E64E58801EF8Q35851975-54B75E6A-F596-4DD5-A8A0-D600BA1F0F16Q35918546-9F39DF61-293D-4E08-B9FE-6E4C939D132DQ36216910-1A2AF938-BEED-4053-B101-EDD5B3666712Q36956418-1DDBD3DF-9B58-44BC-A65E-6A2CA7488E12Q37124741-25269CC8-89EB-434E-B199-3C6BAC1C37DBQ37860950-DA865C1A-E866-4F04-94DA-C4E616CE461AQ38074990-C0A93AA2-4D44-4CEB-BEC8-2225DC8485FEQ38414862-5A5AD8FB-EE13-4A76-94D6-C029545067FCQ38839110-1E528860-18AA-4A27-91EC-BBBFED427377Q38841385-F609AEAE-2074-435F-B797-B788D3315D7CQ38951931-6026494D-057D-4360-97F3-B55F4E958208Q39002111-53167257-2B5D-4B21-97E7-7028C9D9EF45Q39190804-4EDF8E51-5280-40EA-B12F-2D3416DA0655Q39566599-6929225E-D02A-4579-ABDD-6F58121630BFQ41072868-2BC319B0-BC87-4F23-80C0-E7E2FC393AEDQ41382610-306EF990-4CBC-47F6-8035-4CE3B3FF8EB4Q41841139-6D2CAE89-7D91-4BCD-B036-DEAAB3D8EF68Q42007974-DF11B835-9316-406A-9894-590C5F372C9FQ42141429-E7A6A299-1FD0-40BD-B5EF-5390ABB6BF63Q42857879-FC4CEDDF-1522-4AE3-A21E-CB87F92BAB09Q51050274-AE18BD28-25DA-44D8-9EC4-13C1658AF696Q51753740-2BF5EABC-80AB-4847-8D40-AA0F614D18F9Q53614521-6A800C66-1F99-4BBA-B339-833F2D2ABD16Q53700821-5030F10F-146F-493B-9F7B-3C3AB2A219E1Q53839197-6150AF59-AC92-4B5A-B17B-096D79D30008Q57105398-D5EB0761-B260-4C77-A6CF-7890CA7C1B55
P2860
Secondary hormonal therapy for advanced prostate cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Secondary hormonal therapy for advanced prostate cancer.
@ast
Secondary hormonal therapy for advanced prostate cancer.
@en
type
label
Secondary hormonal therapy for advanced prostate cancer.
@ast
Secondary hormonal therapy for advanced prostate cancer.
@en
prefLabel
Secondary hormonal therapy for advanced prostate cancer.
@ast
Secondary hormonal therapy for advanced prostate cancer.
@en
P2093
P1476
Secondary hormonal therapy for advanced prostate cancer.
@en
P2093
Arie S Belldegrun
John S Lam
John T Leppert
Oleg Shvarts
Sreenivas N Vemulapalli
P356
10.1016/S0022-5347(05)00034-0
P407
P577
2006-01-01T00:00:00Z